NautaDutilh advises NewAmsterdam Pharma on USD 726 million business combination with Frazier Lifesciences Acquisition Corp.
On 25 July 2022, NewAmsterdam Pharma, a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, and Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, announced that they have entered into a definitive business combination agreement that would result in NewAmsterdam Pharma Company N.V., a newly formed company, becoming a publicly listed company on Nasdaq.
'With two de-SPAC transactions (NewAmsterdam Pharma and Next.e.GO) signed within the same week, NautaDutilh’s public M&A team underscores its leading position in this field and is off to a great start of H2 2022. We are proud to have acted alongside our friends at Covington & Burling to get to this point.', says lead partner Paul van der Bijl.
Paul van der Bijl and Ruud Smits led the NautaDutilh team which consisted of Joppe Schoute, Daan Hagelstein, Marloes van der Laan, Thomas Castermans and Eline van Marle (Corporate), Nina Kielman (Tax), Liselotte Bekke, Maaike Lelifeld (IP), Arjan Koorevaar (Employment) and Terrence Dom and Tom de Smet (IT/Privacy).